Carolin Weinmann

Universität Mannheim, Mannheim, Baden-Württemberg, Germany

Are you Carolin Weinmann?

Claim your profile

Publications (4)5.97 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to identify patients who suffer from hemodynamic cerebral insufficiency and can benefit from cerebral revascularization procedures, xenon-CT scanning has been established to reliably measure the critical cerebrovascular reserve capacity. As a need for alternative quantification methods arises, this study aims to characterize the significance of both time-to-peak (TTP) and mean transit time (MTT) in perfusion-weighted imaging (PWI) in this particular subset of patients. Ten patients in routine preoperative work-up for cerebral revascularization were prospectively enrolled and underwent both XeCT scanning and PWI. Cerebrovascular reserve capacity (CVRC) was calculated for each region of interest (ROI, n = 504) after administration of a vasoactive stimulus. ROIs were anatomically matched with those of PWI after TTP and MTT were calculated. Highly significant negative correlation was found for TTP and CVRC for all ROIs (r = -0.3954, p < 0.0001; symptomatic ROIs: r = -0.4867, p < 0.0001). Correlation was weak for MTT and CVCR (r = -0.1287; p < 0.01). The optimum threshold for TTP to detect impaired cerebrovascular reactivity in our patient group was 4 s (specificity 90.8%, sensitivity 44.4%) for all ROIs (TTP > 4.4 s for symptomatic ROIs, specificity 88.4%, sensitivity 62.7%). An approximative equation to calculate the probability of pathological findings could be derived from the data. The positive predictive value (PPV) was 0.76 (symptomatic 0.78) with a negative predictive value (NPV) of 0.71 (symptomatic 0.78). While PWI currently is not able to replace XeCT in the direct quantification of CVRC, it may serve as a readily available follow-up tool. A TTP threshold of greater than 4 s allows to confirm a cerebrovascular compromise in a selected high-risk subgroup of patients.
    Neurosurgical Review 10/2008; 32(1):29-35; discussion 35-6. DOI:10.1007/s10143-008-0159-z · 2.18 Impact Factor
  • RöFo - Fortschritte auf dem Gebiet der R 01/2008; 180. DOI:10.1055/s-2008-1073845 · 1.40 Impact Factor
  • C Weinmann · L Gerigk · C Weiss · C Thomé · C Groden · GA Schubert
    RöFo - Fortschritte auf dem Gebiet der R 01/2007; 179. DOI:10.1055/s-2007-977372 · 1.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Treatment of gliomas is multimodal. Magnetic resonance imaging (MRI) in the posttreatment course is of limited value due to therapy-induced changes. In low-grade gliomas (LGG) malignant transformation is of special interest. Our patients and methods were as follows: In nine consecutive patients with LGG we examined the role of bombesin labelled with gallium-68 ((68)Ga-bombesin) studied with positron emission tomography (PET), in addition to fluoro-18-fluorodeoxyglucose ((18)F-FDG) in the differential diagnosis of tumour recurrence versus malignant transformation. We used (68)Ga-bombesin combined with (18)F-FDG-PET in these patients with suspicious new contrast enhancement at the original tumour site or resection cavity in MRI. Eight patients were operated. In one patient, tumour recurrence was most likely as shown by the PET findings and chemotherapy was administered. Our results have shown that in this last mentioned patient after the follow-up period, MRI contrast enhancement was definitively regressive. In the operated patients the tumour was graded as glioblastoma multiforme, gliosarcoma and WHO grade III tumour. In two patients histological grading confirmed the PET findings without malignant transformation. In all of the 9 patients the combination of (68)Ga-bombesin and (18)F-FDG-PET predicted correctly malignant transformation or recurrence of the initial tumour grade which shows that (68)Ga-bombesin-PET can provide additional important information to detect a malignant transformation. In conclusion it is crucial for the patient to differentiate the nature of the new lesion in order to endorse an aggressive or non-aggressive treatment.
    Hellenic journal of nuclear medicine 11(3):149-52. · 0.99 Impact Factor